**UNITED      STATES**

**SECURITIES      AND EXCHANGE COMMISSION**

**Washington,      D.C. 20549**

----

**FORM      10-K/A**

**Amendment      No. 1 to Form 10-K/A**

**Filed      on May 10, 2006**

**        ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT      OF      1934**

**For      the fiscal year ended December 31, 2005.**

**OR**

**        TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE      ACT      OF 1934**

**For      the transition period from ________ to ________.**

**Commission      File Number 000-30929**

----

**KERYX      BIOPHARMACEUTICALS, INC.**

**(Exact      name of registrant as specified in its charter)**

| **Delaware**(State                or other jurisdiction ofincorporation                or organization)                             | **13-4087132**(I.R.S.                EmployerIdentification                No.) |
|-------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
|                                                                                                                                |
| **750                Lexington Avenue****New                York, New York**(Address                of principal executive offices) |  **10022**(Zip                Code)                                        |

**Registrant’s      telephone number, including area code: (212) 531-5965**

**Securities      registered pursuant to Section 12(b) of the Act:**

**Securities      registered pursuant to Section 12(g) of the Act:**

----

| Large                  accelerated filer £ | Accelerated                  filer x | Non-accelerated                  filer £ |
|-------------------------------------------------|--------------------------------------|-----------------------------------------------|

**DOCUMENTS      INCORPORATED BY REFERENCE**

----

**Explanatory      Note**

----

**PART      IV**

**ITEM      15. EXHIBITS and FINANCIAL STATEMENT SCHEDULES**

**(a)**
**3.**
**Exhibits**

| **Exhibit**                                                                                                                            |   |                                                                                                                                                                                                                                       |
|----------------------------------------------------------------------------------------------------------------------------------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **Number**                                                                                                                             |   | **Exhibit                Description**                                                                                                                                                                                                     |
|                                                                                                                                   |   |                                                                                                                                                                                                                                       |
| 10.21*                                                                                                                                 |   | License                Agreement between Keryx Biopharmaceuticals, Inc. and Panion & BF                Biotech,  Inc.                dated as of November 7, 2005.                                                                |
| 31.1                                                                                                                                   |   | Certification                of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a),                as                adopted  pursuant                to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 17, 2006. |
| 31.2                                                                                                                                   |   | Certification                of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a),                as                adopted  pursuant                to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 17, 2006. |
| _______*                Confidential treatment has been requested with respect to the omitted                portions of this exhibit. |

----

|   | **KERYX                BIOPHARMACEUTICALS, INC.** |
|--------|---------------------------------------------------|
|   | By:                                               | /s/                Ronald C. Renaud, Jr. |
|   |                                              | **Ronald                C. Renaud, Jr.****Senior                Vice President, Chief Financial Officer,****Secretary                and Treasurer** |
|   |                                              |   |

----

**EXHIBIT      INDEX**

| **Exhibit**                                                                                                                                                                                                     |   |                                                                                                                                                                                                                                                                |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **Number**                                                                                                                                                                                                      |   | **Exhibit                  Description**                                                                                                                                                                                                                            |
|                                                                                                                                                                                                            |   |                                                                                                                                                                                                                                                                |
| 10.21*                                                                                                                                                                                                          |   | License                  Agreement between Keryx Biopharmaceuticals, Inc. and Panion & BF                  Biotech,  Inc.                  dated as of November 7, 2005.                                                                                   |
| 31.1                                                                                                                                                                                                            |   | Certification                  of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a),                  as                  adopted  pursuant                  to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 17,                  2006. |
| 31.2                                                                                                                                                                                                            |   | Certification                  of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a),                  as                  adopted  pursuant                  to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 17,                  2006. |
| __________*                             Confidential treatment has been requested with respect to the                  omitted portions of this exhibit. |

----